NHS Approves First Daily Pill for Endometriosis Treatment

The new relugolix combination therapy offers a faster, at-home alternative for patients whose previous treatments have failed.

Relugolix-estradiol-norethisterone, the first long-term daily pill for endometriosis, has been approved for NHS use in England.
The drug blocks hormones contributing to the condition while providing essential hormone replacement, distinguishing it from injectable treatments.
Eligibility is limited to around 1,000 women annually who have not found relief through other medical or surgical interventions.
Endometriosis affects 1.5 million women in the UK, with symptoms including severe pain, fatigue, and fertility difficulties, often taking nine years to diagnose.
The approval follows initial rejection by Nice, with additional evidence addressing concerns about the drug's cost-effectiveness and efficacy.